Related references
Note: Only part of the references are listed.Systemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma
Bryan D. Choi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Therapeutic application of monoclonal antibodies in cancer: advances and challenges
Helmout Modjtahedi et al.
BRITISH MEDICAL BULLETIN (2012)
Recognition of Glioma Stem Cells by Genetically Modified T Cells Targeting EGFRvIII and Development of Adoptive Cell Therapy for Glioma
Richard A. Morgan et al.
HUMAN GENE THERAPY (2012)
T cells become licensed in the lung to enter the central nervous system
Francesca Odoardi et al.
NATURE (2012)
CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 20052009
Therese A. Dolecek et al.
NEURO-ONCOLOGY (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Effector T-Cell Infiltration Positively Impacts Survival of Glioblastoma Patients and Is Impaired by Tumor-Derived TGF-β
Jennifer Lohr et al.
CLINICAL CANCER RESEARCH (2011)
Bispecific antibodies engage T cells for antitumor immunotherapy
Bryan D. Choi et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Cytotoxic Enhancement of a Bispecific Diabody by Format Conversion to Tandem Single-chain Variable Fragment (taFv) THE CASE OF THE hEx3 DIABODY
Ryutaro Asano et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma
John H. Sampson et al.
NEURO-ONCOLOGY (2011)
Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Claudia Bluemel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Dacarbazine Treatment before Peptide Vaccination Enlarges T-Cell Repertoire Diversity of Melan-A-Specific, Tumor-Reactive CTL in Melanoma Patients
Belinda Palermo et al.
CANCER RESEARCH (2010)
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
Maria-del-Mar Inda et al.
GENES & DEVELOPMENT (2010)
CD8+T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival
Isaac Yang et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
Ralf Lutterbuese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Cornelia Haas et al.
IMMUNOBIOLOGY (2009)
Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients
Paola Nistico et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
John H. Sampson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
What's fueling the biotech engine-2008
Saurabh Aggarwal
NATURE BIOTECHNOLOGY (2009)
Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3
Maria Amann et al.
CANCER RESEARCH (2008)
Fully human antibodies from transgenic mouse and phage display platforms
Nils Lonberg
CURRENT OPINION IN IMMUNOLOGY (2008)
Intercellular transfer of the oncogenic receptor EGFrvIII by microvesicles derived from tumour cells
Khalid Al-Nedawi et al.
NATURE CELL BIOLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class
Klaus Brischwein et al.
JOURNAL OF IMMUNOTHERAPY (2007)
Advances in radiation therapy for brain tumors
Volker W. Stieber et al.
NEUROLOGIC CLINICS (2007)
The 2007 WHO classification of tumours of the central nervous system
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2007)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E. Pelloski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors
Andrew M. Scott et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
FDA drug approval summary: Panitumumab (Vectibix (TM))
Ruthann M. Giusti et al.
ONCOLOGIST (2007)
FcRn: the neonatal Fc receptor comes of age
Derry C. Roopenian et al.
NATURE REVIEWS IMMUNOLOGY (2007)
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
W Stummer et al.
LANCET ONCOLOGY (2006)
MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating established tumors
K Brischwein et al.
MOLECULAR IMMUNOLOGY (2006)
Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs on MHC class I-negative tumor cells
S Offner et al.
MOLECULAR IMMUNOLOGY (2006)
Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct
P Hoffmann et al.
INTERNATIONAL JOURNAL OF CANCER (2005)
Immunogenicity of engineered antibodies
WYK Hwang et al.
METHODS (2005)
Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
B Schlereth et al.
CANCER RESEARCH (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
Selecting and screening recombinant antibody libraries
HR Hoogenboom
NATURE BIOTECHNOLOGY (2005)
Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility
MW Pedersen et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells:: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv
T Korn et al.
JOURNAL OF GENE MEDICINE (2004)
Inhibition of the type III epidermal growth factor receptor variant mutant receptor by dominant-negative EGFR-CD533 enhances malignant glioma cell radiosensitivity
G Lammering et al.
CLINICAL CANCER RESEARCH (2004)
Constitutive EGFR signaling confers a motile phenotype to neural stem cells
JA Boockvar et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2003)
Human cerebrospinal fluid central memory CD4+ T cells:: Evidence for trafficking through choroid plexus and meninges via P-selectin
P Kivisäkk et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Effect of domain order on the activity of bacterially produced bispecific single-chain Fv antibodies
SM Kipriyanov et al.
JOURNAL OF MOLECULAR BIOLOGY (2003)
Adalimumab, a fully human anti-tumor necrosis factor a monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate - The ARMADA trial
ME Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2003)
Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody
T Dreier et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Expression of the neonatal Fc receptor (FcRn) at the blood-brain barrier
F Schlachetzki et al.
JOURNAL OF NEUROCHEMISTRY (2002)
Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor
M Nagane et al.
JOURNAL OF NEUROSURGERY (2001)
Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies
B Stockmeyer et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2001)
Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters β-tubulin isotype expression
RB Montgomery et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)